More News

ALLOX raises $10.5m to scale allosteric drug discovery platform and build pipeline

Jim Cornall -
ALLOX, a biotechnology company developing a high-throughput, experimental-first platform to discover and exploit allosteric sites and other regulatory regions...

Worm study may have implications for Alzheimer’s and Huntington’s

Jim Cornall -
A new study has discovered that reducing a cellular process called UFMylation helped worms better cope with toxic protein...

Blocking immune cell signals could make brain tumours easier to remove

Jim Cornall -
In a new study published in Cancer Cell, researchers at VIB-KU Leuven in Belgium reduced the spread of glioblastoma...

Exogenus Therapeutics leads €13m consortium to advance new secretome-based therapy for osteoarthritis

Jim Cornall -
The ExoCordOA consortium has launched a five-year, €13m project, funded by Horizon Europe, to advance extracellular vesicle-enriched secretome therapies...

Base to Base biotech podcast 82: Restoring blood flow to the heart and tackling HHT

Jim Cornall -
This week, we have a conversation with Philip Brainin, CEO of Isomab, about restoring blood flow to the heart,...

Early results from “encouraging” pancreatic cancer study

Jim Cornall -
ImPact Biotech has announced the successful completion of treatment in part A of its phase 1 clinical trial in...

Familiar Therapeutics launches to close gap between human and veterinary medicine

Jim Cornall -
Familiar Therapeutics has launched with $5m in seed funding to bring the advances of modern human medicine to dogs...

Scientists create white blood cell with memory of how to fight off winter flu bugs

Jim Cornall -
Researchers at the University of Southampton in the UK are developing killer cells, a type of white blood cell,...

Topline results from metastatic breast cancer phase 3 trial

Jim Cornall -
BioNTech SE and DualityBiologics (Suzhou) Co., Ltd. have announced that the DYNASTY-Breast02 global phase 3 clinical trial met its...

Updated prostate cancer results show anti-tumour activity

Jim Cornall -
AdvanCell has announced updated results from the TheraPb phase 1 clinical trial evaluating ADVC001, an investigational lead-212 PSMA-targeted alpha...

Gesynta Pharma continues endometriosis work

Jim Cornall -
Gesynta Pharma AB has completed enrolment in NOVA, its phase 2 clinical proof-of-concept and dose-finding trial. With 213 patients...

First-in-human circular RNA therapy for radiation-induced xerostomia

Jim Cornall -
RiboX Therapeutics has announced the publication of a peer-reviewed Research Letter in The New England Journal of Medicine (NEJM)...

Data show unresectable patients becoming eligible for surgery

Jim Cornall -
Brenus Pharma has announced first data from the phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were...

Personalised cancer vaccine with immunotherapy reduces melanoma recurrence after surgery

Jim Cornall -
Adding a personalised mRNA-based cancer vaccine to immunotherapy after surgery for high-risk melanoma reduced the risk of recurrence or...

AI drug choices may cost millions

Jim Cornall -
Large language models (LLMs), such as ChatGPT and Claude, are increasingly being used to provide health information to the...

Researchers reprogramme pancreatic cancer tumour microenvironment

Jim Cornall -
Pancreatic cancer is one of the most aggressive and difficult-to-treat cancers. One reason for its resistance to therapy is...

Base to Base biotech podcast 81: Breakthrough in shrinking tumours and restoring mitochondrial metabolism to address obesity

Jim Cornall -
This week, we talk about mitochondria and obesity with Jon Rees, co-founder and CEO of MitoRx Therapeutics, and also...

New bacteria discovered in DNA samples from prostate cancer patients

admin -
University of East Anglia researchers have discovered the genetic blueprints of 18 new bacterial species collected from prostate cancer...

Estuary Biotherapeutics launches with $103m to develop gene therapies for kidney disease

Jim Cornall -
Estuary Biotherapeutics, Inc. has launched with $103m in total committed financing. The financing will support advancement of the company’s two...

Data show reduction in skin epigenetic age and systemic inflammatory biomarkers

Jim Cornall -
Rubedo Life Sciences has revealed new phase 1b clinical findings for RLS-1496, its lead investigational GPX4 modulator. In patients with...

Blood proteins may offer clues to gut health in coeliac disease

Jim Cornall -
Coeliac disease is an autoimmune condition in which the immune system reacts adversely to gluten. Eating gluten causes inflammation...